PIV和AAPR对非小细胞肺癌伴脑转移患者的预后评估价值

doi:10.3969/j.issn.1004-616x.2023.01.008

Abstract

Abstract: OBJECTIVE: To investigate prognostic values of pan-Immune-inflammation index (PIV) and albumin to alkaline phosphatase ratio (AAPR) in non-small cell lung cancers with brain metastasis. METHODS: From the Second Affiliated Hospital of Zhengzhou University，the case data of 102 non-small-cell lung cancer patients with brain metastasis from December 2015 to April 2022 were retrospectively analyzed. The data included patients' basic clinicopathological characteristics，head radiotherapy status，baseline laboratory data，etc. PIV，AAPR，systemic immune inflammatory index (SII)，neutrophil/lymphocyte ratio (NLR)，derived neutrophil/lymphocyte ratio (dNLR)，platelet/lymphocyte ratio (PLR) and lymphocyte/monocyte ratio (LMR) were calculated using the blood routine and liver function test results. The best cut-off values of PIV，AAPR，etc for predicting the prognosis of the cancer cases were calculated using the X-tile software. χ² test or Fisher--s-exact-test-was used to evaluate correlations between PIV，AAPR and various clinicopathological indicators. Univariate and multivariate Cox proportional hazard regression models were used to analyze possible correlations between these variables and clinical outcomes，and to explore factors affecting the survival of the patients. Survival curves were drawn using the R software. RESULTS: The cutoff values for PIV，AAPR，SII，NLR，dNLR，PLR，and LMR were 221.9，0.6，1 039.4，5.2，4.0，223.7，and 4.5，respectively. The univariate Cox regression model showed that the survival curves of PIV，AAPR，SII，NLR，dNLR，LMR in different levels were statistically significant (P<0.05). The multivariate Cox regression model showed that PIV and AAPR had a certain impact on the prognosis of patients (P<0.05). CONCLUSION: Our results show that high PIV (≥221.9) and low AAPR (<0.6) were related to poor clinical outcomes. Thus，PIV and AAPR can be used as biomarkers to predict prognosis of non-small cell lung cancer patients with brain metastasis.

Key words: non-small cell lung cancer, brain metastasis, pan-immune-inflammation value, albumin, alkaline phosphatase

CLC Number:

R734.2

JIN Shuang, LI Kun, CHEN Hongrun, ZHANG Zhongmian. Prognostic value of PIV and AAPR in patients with non-small cell lung cancer with brain metastasis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 43-48.

References

[1] 秦叔逵, 苗静, 韩宝惠, 等. 重组人血管内皮抑制素联合常用含铂化疗方案治疗晚期非小细胞肺癌的Ⅳ期临床研究[J]. 临床肿瘤学杂志, 2019, 24(4):289-298.
[2] 孙爽, 门玉, 惠周光. 非小细胞肺癌脑转移高危因素研究进展[J]. 中国肺癌杂志, 2022, 25(3):193-200.
[3] YANG M, ZHANG Q, GE Y Z, et al. Prognostic roles of inflammation- and nutrition-based indicators for female patients with cancer[J]. J Inflamm Res, 2022, 15:3573-3586.
[4] FUCÀ G, GUARINI V, ANTONIOTTI C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer:results from a pooled-analysis of the Valentino and TRIBE first-line trials[J]. Br J Cancer, 2020, 123(3):403-409.
[5] PÉREZ-MARTELO M, GONZÁLEZ-GARCÍA A, VIDAL-ÍNSUA Y, et al. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy[J]. Sci Rep, 2022, 12:6893.
[6] TOPKAN E, SELEK U, KUCUK A, et al. Low pre-Chemoradiotherapy Pan-immune-inflammation value (PIV) measures predict better survival outcomes in locally advanced pancreatic adenocarcinomas[J]. J Inflamm Res, 2022, 15:5413-5423.
[7] YAZGAN S C, YEKEDÜZ E, UTKAN G, et al. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors[J]. Prostate, 2022, 82(15):1456-1461.
[8] ŞAHIN A B, CUBUKCU E, OCAK B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy[J]. Sci Rep, 2021, 11:14662.
[9] FUCÀ G, BENINATO T, BINI M, et al. The pan-immune-inflammation value in patients with metastatic melanoma receiving first-line therapy[J]. Targ Oncol, 2021, 16(4):529-536.
[10] LI J H, ZUO M R, ZHOU X W, et al. Prognostic significance of preoperative albumin to alkaline phosphatase ratio in patients with glioblastoma[J]. J Cancer, 2021, 12(19):5950-5959.
[11] ZHANG F, LU S X, HU K S, et al. Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy[J]. Int J Hyperth, 2021, 38(1):1-10.
[12] ZHU X Y, CHEN D N, LI S J, et al. Albumin-to-alkaline phosphatase ratio as a novel and promising prognostic biomarker in patients undergoing esophagectomy for carcinoma:a propensity score matching study[J]. Front Oncol, 2021, 11:764076.
[13] WON I, SHIM S R, KIM S I, et al. Albumin-to-alkaline phosphatase ratio as a novel prognostic factor in patients undergoing nephrectomy for non-metastatic renal cell carcinoma:propensity score matching analysis[J]. Clin Genitourin Cancer, 2022, 20(3):e253-e262.
[14] CERTO M, TSAI C H, PUCINO V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments[J]. Nat Rev Immunol, 2021, 21(3):151-161.
[15] 覃凤娴, 刘小勇, 陈翔. 肿瘤相关中性粒细胞在肿瘤靶向治疗中的研究进展[J]. 中国免疫学杂志, 2021, 37(21):2647-2652.
[16] 周发权, 陈师, 孙红玉, 等. 系统免疫炎症指数与胰腺癌患者预后关系的系统评价和Meta分析[J]. 中国普通外科杂志, 2020, 29(9):1076-1083.
[17] OLINGY C E, DINH H Q, HEDRICK C C. Monocyte heterogeneity and functions in cancer[J]. J Leukoc Biol, 2019, 106(2):309-322.
[18] LI X G, LI B T, ZENG H Y, et al. Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer[J]. Future Oncol, 2019, 15(9):995-1006.
[19] ZHAO H Z, CHEN X Y, ZHANG W H, et al. Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer[J]. Front Surg, 2022, 9:996844.
[20] LIN F, ZHANG L P, XIE S Y, et al. Pan-immune-inflammation value:a new prognostic index in operative breast cancer[J]. Front Oncol, 2022, 12:830138.
[21] ZENG R, LIU F, FANG C, et al. PIV and PILE score at baseline predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients[J]. Front Immunol, 2021, 12:724443.
[22] CHEN X, HONG X, CHEN G, et al. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor[J]. Transl Oncol, 2022, 17:101338.
[23] ZHOU S Z, JIANG W, WANG H L, et al. Predictive value of pretreatment albumin-to-alkaline phosphatase ratio for overall survival for patients with advanced non-small cell lung cancer[J]. Cancer Med, 2020, 9(17):6268-6280.

Prognostic value of PIV and AAPR in patients with non-small cell lung cancer with brain metastasis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	QI Jiankao, TANG Xiao, SUN Shihui, KOU Yanfang, CUI Zhiqin. Growth inhibition of non-small cell lung cancers by Zaoci decotion in combination with cisplatin and gemcitabine [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 366-372,403.
[2]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[3]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.
[4]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[5]	LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.
[6]	YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226.
[7]	ZHU Jiawei, HU Xiao, WANG Xijun, WANG Yaru, FENG Lin, XIAO Ting. Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 89-95.
[8]	ZHANG Jing, TENG Yu, ZHAO Xiaoting, JIANG Mei, YUE Wentao. Effects of the inhibitor of Wnt production 2 on cell migration and invasion in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 245-250.
[9]	SONG Jie, LI Ping, YU Xuexin, FENG Lin, GAO Yanning, XIAO Ting. Expression of Syntenin in non-small cell lung cancer tissues and its relationship with overall survival of patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 102-105.
[10]	ZHAI Xiaoran, JIANG Mei, ZHAO Xiaoting, GU Meng, YUE Wentao. Clinical significance of PFTK1 expression in human non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 231-235.
[11]	WU Juan, DU Yun, WANG Heng, WU Jianing, ZHAO Yinhuan, WANG Rui, ZHANG Yan, JI Xiaokun. Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 27-31.
[12]	YOU Shuping, ZHAO Jun, MUKARAM Tudimat, MA Long, ZHANG Shilei, LIU Tao. The effects of cistanche phenylethanoid glycosides on TGF-β1 expression of rats with hepatic fibrosis induced by BSA [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(6): 409-414.
[13]	LING Bing，FENG Lin，CHENG Shu-jun. Effect of DENND2Don the cisplatinum cytotoxicity in H1299 cells by regulating PARP1 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(2): 87-90.
[14]	ZHI Yuan，LIU Hai-bo，GENG Gui-ying，CUI Wen-ming，LIU Shan，XU Hai-bin*. Genetic toxicity of transgenic human α-lactalbumin powdered milk [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(2): 124-126.
[15]	DI Chan-juan1，2，LI Hai-bing2，3，HAN Chun-guang2，HU Ming2，YUAN Mei-ru2，LIU Yong-xue2，*. Characteristics and identification of an ovalbumin-induced allergic rhinitis model in guinea pigs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2012, 24(6): 440-443.